Cargando…

Differences in serum cytokine levels distinguish between clinically noninvasive lung adenocarcinoma and invasive lung adenocarcinoma: A cross‐sectional study

BACKGROUND: Lung cancer incidence and mortality remain high and are now the leading cause of cancer‐related death. Lung adenocarcinoma (LUAD) is one of the main histological subtypes of lung cancer. Previous studies have shown the role of inflammation in the development of lung cancer, but the relat...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Bingjie, Wang, Xianzhao, Qin, Yueyang, Cao, Leiqun, Zhang, Congcong, Meng, Fanyu, Chen, Changqiang, Wang, Jiayi, Ma, Lifang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486205/
https://www.ncbi.nlm.nih.gov/pubmed/37692791
http://dx.doi.org/10.1002/hsr2.1522
_version_ 1785102956056543232
author Zeng, Bingjie
Wang, Xianzhao
Qin, Yueyang
Cao, Leiqun
Zhang, Congcong
Meng, Fanyu
Chen, Changqiang
Wang, Jiayi
Ma, Lifang
author_facet Zeng, Bingjie
Wang, Xianzhao
Qin, Yueyang
Cao, Leiqun
Zhang, Congcong
Meng, Fanyu
Chen, Changqiang
Wang, Jiayi
Ma, Lifang
author_sort Zeng, Bingjie
collection PubMed
description BACKGROUND: Lung cancer incidence and mortality remain high and are now the leading cause of cancer‐related death. Lung adenocarcinoma (LUAD) is one of the main histological subtypes of lung cancer. Previous studies have shown the role of inflammation in the development of lung cancer, but the relationship between cytokines and LUAD is still unclear. To further differentiate and explore the association of cytokines with the risk of non‐invasive and invasive LUAD, we studied and assessed serum cytokine levels in patients with two types of LUAD. METHODS: A cohort study of 90 non‐invasive LUAD and 90 invasive LUAD was retrospectively included, and the clinical characteristics were recorded in detail. The differences in the levels of 12 serum cytokines (IFN‐α, IFN‐γ, IL‐10, IL‐12P70, IL‐17A, IL‐1β, IL‐2, IL‐4, IL‐5, IL‐6, IL‐8, and TNF‐α) between the two groups of patients with LUAD were analyzed and evaluated. And we evaluated the clinical value of cytokine differential diagnosis of invasive LUAD based on receiver operating characteristics (ROC) curves. RESULTS: The mean age of the patients was 56.6 years, and the proportions of males and females were 38.9% and 61.1%, respectively. IFN‐α, IL‐1β, IL‐2, IL‐6, TNF‐α, IL‐4, and IL‐8 were significantly increased in patients with invasive LUAD compared with the non‐invasive LUAD group. Further research found that smoking is an important factor, with changes in the four cytokines IL‐1β, IL‐6, IL‐8, and TNF‐α being significantly higher in the smoking group of patients with invasive LUAD. It can be seen from the area under the curve that IL‐1β and IL‐2 have a significant differential diagnosis. CONCLUSIONS: We observed differences in preoperative serum cytokine levels between patients with invasive and non‐invasive LUAD, which may serve as potential serum biomarkers for clinical differential diagnosis and disease progression assessment.
format Online
Article
Text
id pubmed-10486205
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-104862052023-09-09 Differences in serum cytokine levels distinguish between clinically noninvasive lung adenocarcinoma and invasive lung adenocarcinoma: A cross‐sectional study Zeng, Bingjie Wang, Xianzhao Qin, Yueyang Cao, Leiqun Zhang, Congcong Meng, Fanyu Chen, Changqiang Wang, Jiayi Ma, Lifang Health Sci Rep Original Research BACKGROUND: Lung cancer incidence and mortality remain high and are now the leading cause of cancer‐related death. Lung adenocarcinoma (LUAD) is one of the main histological subtypes of lung cancer. Previous studies have shown the role of inflammation in the development of lung cancer, but the relationship between cytokines and LUAD is still unclear. To further differentiate and explore the association of cytokines with the risk of non‐invasive and invasive LUAD, we studied and assessed serum cytokine levels in patients with two types of LUAD. METHODS: A cohort study of 90 non‐invasive LUAD and 90 invasive LUAD was retrospectively included, and the clinical characteristics were recorded in detail. The differences in the levels of 12 serum cytokines (IFN‐α, IFN‐γ, IL‐10, IL‐12P70, IL‐17A, IL‐1β, IL‐2, IL‐4, IL‐5, IL‐6, IL‐8, and TNF‐α) between the two groups of patients with LUAD were analyzed and evaluated. And we evaluated the clinical value of cytokine differential diagnosis of invasive LUAD based on receiver operating characteristics (ROC) curves. RESULTS: The mean age of the patients was 56.6 years, and the proportions of males and females were 38.9% and 61.1%, respectively. IFN‐α, IL‐1β, IL‐2, IL‐6, TNF‐α, IL‐4, and IL‐8 were significantly increased in patients with invasive LUAD compared with the non‐invasive LUAD group. Further research found that smoking is an important factor, with changes in the four cytokines IL‐1β, IL‐6, IL‐8, and TNF‐α being significantly higher in the smoking group of patients with invasive LUAD. It can be seen from the area under the curve that IL‐1β and IL‐2 have a significant differential diagnosis. CONCLUSIONS: We observed differences in preoperative serum cytokine levels between patients with invasive and non‐invasive LUAD, which may serve as potential serum biomarkers for clinical differential diagnosis and disease progression assessment. John Wiley and Sons Inc. 2023-09-08 /pmc/articles/PMC10486205/ /pubmed/37692791 http://dx.doi.org/10.1002/hsr2.1522 Text en © 2023 The Authors. Health Science Reports published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research
Zeng, Bingjie
Wang, Xianzhao
Qin, Yueyang
Cao, Leiqun
Zhang, Congcong
Meng, Fanyu
Chen, Changqiang
Wang, Jiayi
Ma, Lifang
Differences in serum cytokine levels distinguish between clinically noninvasive lung adenocarcinoma and invasive lung adenocarcinoma: A cross‐sectional study
title Differences in serum cytokine levels distinguish between clinically noninvasive lung adenocarcinoma and invasive lung adenocarcinoma: A cross‐sectional study
title_full Differences in serum cytokine levels distinguish between clinically noninvasive lung adenocarcinoma and invasive lung adenocarcinoma: A cross‐sectional study
title_fullStr Differences in serum cytokine levels distinguish between clinically noninvasive lung adenocarcinoma and invasive lung adenocarcinoma: A cross‐sectional study
title_full_unstemmed Differences in serum cytokine levels distinguish between clinically noninvasive lung adenocarcinoma and invasive lung adenocarcinoma: A cross‐sectional study
title_short Differences in serum cytokine levels distinguish between clinically noninvasive lung adenocarcinoma and invasive lung adenocarcinoma: A cross‐sectional study
title_sort differences in serum cytokine levels distinguish between clinically noninvasive lung adenocarcinoma and invasive lung adenocarcinoma: a cross‐sectional study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486205/
https://www.ncbi.nlm.nih.gov/pubmed/37692791
http://dx.doi.org/10.1002/hsr2.1522
work_keys_str_mv AT zengbingjie differencesinserumcytokinelevelsdistinguishbetweenclinicallynoninvasivelungadenocarcinomaandinvasivelungadenocarcinomaacrosssectionalstudy
AT wangxianzhao differencesinserumcytokinelevelsdistinguishbetweenclinicallynoninvasivelungadenocarcinomaandinvasivelungadenocarcinomaacrosssectionalstudy
AT qinyueyang differencesinserumcytokinelevelsdistinguishbetweenclinicallynoninvasivelungadenocarcinomaandinvasivelungadenocarcinomaacrosssectionalstudy
AT caoleiqun differencesinserumcytokinelevelsdistinguishbetweenclinicallynoninvasivelungadenocarcinomaandinvasivelungadenocarcinomaacrosssectionalstudy
AT zhangcongcong differencesinserumcytokinelevelsdistinguishbetweenclinicallynoninvasivelungadenocarcinomaandinvasivelungadenocarcinomaacrosssectionalstudy
AT mengfanyu differencesinserumcytokinelevelsdistinguishbetweenclinicallynoninvasivelungadenocarcinomaandinvasivelungadenocarcinomaacrosssectionalstudy
AT chenchangqiang differencesinserumcytokinelevelsdistinguishbetweenclinicallynoninvasivelungadenocarcinomaandinvasivelungadenocarcinomaacrosssectionalstudy
AT wangjiayi differencesinserumcytokinelevelsdistinguishbetweenclinicallynoninvasivelungadenocarcinomaandinvasivelungadenocarcinomaacrosssectionalstudy
AT malifang differencesinserumcytokinelevelsdistinguishbetweenclinicallynoninvasivelungadenocarcinomaandinvasivelungadenocarcinomaacrosssectionalstudy